Literature DB >> 16174674

Lithium: a review of its metabolic adverse effects.

Callum Livingstone1, Hagan Rampes.   

Abstract

Treatment with lithium has long been recognized to be associated with metabolic adverse effects notably hypothyroidism, hyperparathyroidism, weight gain and nephrogenic diabetes insipidus. It is important that clinicians prescribing lithium are aware of these adverse effects and have a strategy for their detection and management. We review aspects of these actions of lithium including their prevalence, risk factors, biochemical changes involved and management, and discuss some advances that have been made in their understanding in recent years.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16174674     DOI: 10.1177/0269881105057515

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  43 in total

1.  How does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications.

Authors:  Dean Elbe; Robert Savage
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2010-02

Review 2.  Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.

Authors:  A A Verhaegen; L F Van Gaal
Journal:  J Endocrinol Invest       Date:  2017-06-28       Impact factor: 4.256

3.  Lithium-induced transient euthyroid hyperthyroxinemia: a case report.

Authors:  Lakshminarayana Chekuri; Jaquelyn R Lange; Purushottam B Thapa
Journal:  Prim Care Companion CNS Disord       Date:  2014

4.  Medical Co-morbidities Among Patients with Severe Mental Illnesses in a Community Health Facility in Nigeria.

Authors:  Victor Olufolahan Lasebikan; Joachim Azegbeobor
Journal:  Community Ment Health J       Date:  2016-11-25

Review 5.  Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.

Authors:  Chaya G Bhuvaneswar; Ross J Baldessarini; Veronica L Harsh; Jonathan E Alpert
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

6.  GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity.

Authors:  Reena Rao; Satish Patel; Chuanming Hao; James Woodgett; Raymond Harris
Journal:  J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 10.121

7.  Standards of lithium monitoring in mental health Ttrusts in the UK.

Authors:  Noel Collins; Thomas Re Barnes; Amber Shingleton-Smith; David Gerrett; Carol Paton
Journal:  BMC Psychiatry       Date:  2010-10-12       Impact factor: 3.630

8.  Lithium-induced sinus node dysfunction at therapeutic levels.

Authors:  Ranjan K Shetty; G Vivek; Amrita Parida; Shashikanth Chetty
Journal:  BMJ Case Rep       Date:  2013-01-22

Review 9.  Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  NR2B subunit of the NMDA glutamate receptor regulates appetite in the parabrachial nucleus.

Authors:  Qi Wu; Ruimao Zheng; Dollada Srisai; G Stanley McKnight; Richard D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.